No Data
No Data
Cansino (688185.SH): Register of A-share shareholders on May 10, with 21,183 holders
Gelonghui, May 13 | Cansino (688185.SH) said on the investor interactive platform that according to the company's A-share shareholder register issued by China Securities Registration and Settlement Co., Ltd. on May 10, 2024, the number of holders is 21,183.
Changes in Hong Kong stocks | Cansino Biotech (06185) rose more than 6% in the intraday period, UBS says MCv4 business revenue may increase 50% this year
The Zhitong Finance App learned that Cansino Biotech (06185) rose more than 6% in the intraday period. As of press release, it had risen 4% to HK$20.8, with a turnover of HK$24.9353 million. UBS published research stating that as the number of births falls further, the market focus will continue to shift from child vaccines to adult vaccines. At the same time, it is predicted that, driven by the increasing penetration rate of the MCv4 vaccine, Cansino's MCv4 business revenue will increase by 50% in 2024. According to the bank, the penetration rate of the Cansino Biotech MCV4 vaccine is relatively low, and the launch of the new product brings rich catalysts, setting the target price of Cansino H shares at
Cansino Biotech (06185.HK) Purchases Structured Deposits
Glonghui, May 8, 丨 Cansino Biotech (06185.HK) announced that on May 8, 2024, the company and Bohai Bank signed a structured deposit agreement VI with Bohai Bank. Based on this, the company agreed to purchase a structured deposit with a principal amount of RMB 200 million from Bohai Bank.
Changes in Hong Kong stocks | Cansino Biotech fell more than 5%, and its loss increased to 170 million yuan in the first quarter. It plans to sign a product transfer and technology licensing agreement with Shanghai Pharmaceutical Cansino
Cansino Biotech (06185) fell by more than 5%. As of press release, it was down 5.11% to HK$17.84, with a turnover of HK$15.417,300.
Cansino Biotech (06185) plans to transfer AD5-eBoV and its global commercialization rights to the drug Cansino
Cansino Biotech (06185) announced that the company plans to sign a “Product Transfer and Technology License Agreement” with Shanghai Pharmaceutical Cansino, approximately...
康希諾生物:截至2024年3月31日止三個月的第一季度報告
No Data